Daiichi SankyoDaiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has established a new Japanese vaccine research unit to be located in its Kasai R&D Center (Edogawa-ku, Tokyo).

Daiichi Sankyo has been strengthening and expanding its vaccine business in line with the Hybrid Business Model featured in its 2nd Mid-term Business Management Plan (FY2010-2012). In April 2011, Daiichi Sankyo set up a research unit inside the National Institute of Biomedical Innovation and is already performing exploratory vaccine research and continuously reinforcing and expanding R&D for new adjuvants.

Through the establishment of its new vaccine research unit, Daiichi Sankyo aims to enhance and broaden exploratory research for vaccines to prevent infectious diseases and to make pharmacological assessments for vaccines (immunogenicity of candidate antigens and ability to fend off infection).

Now, with two vaccine research units and partnerships with organizations inside and outside of the Group, Daiichi Sankyo is poised to fully realize its dedication to producing new vaccines through continuing research efforts and to supplying safe and effective existing vaccines to the healthcare professionals and other persons in Japan who are waiting for them.

About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain.